Buying Innovation in Web Services



By Scott Lundstrom

Dec 2005 / Jan 2006 | It’s no secret that Web services are the hottest thing going in enterprise architecture. Every major vendor now has a services-oriented spin on its product, and every customer has a Web services requirement section in his or her RFPs. Rivaling the hype that surrounded the emergence of client/server architectures, and then the ensuing object wars between COM and CORBA, jaded customers are now being inundated with Web services offerings from their suppliers. Many customers have been skeptical based on the poor returns they have seen by blindly following a single vendor’s dogmatic approach to architecture. While this skepticism is understandable, it looks as if 2006 will be the year that service-based architectures break out of the hype cycle and move from pilots to production.

Web services-chart.gif

While many of us have been talking about Web services for five years now, most companies have spent the last two years in the pilot phase. Many companies were in the process of creating a business case for a focused rollout of the technology. Recent data from the Life Science Insights Leading Indicators Panel suggests that in the next 12 months we will see widespread adoption of service-oriented architectures in the life science industry.

Like previous generations of application architecture, Web services represent a fundamental shift in how computing resources are deployed and integrated. Service-oriented architectures differ from previous approaches by avoiding vendor lock in, while fostering open data standards. Open standards surrounding the collection and exchange of data are essential to any broad-based deployment of Web services. This is especially true in areas of the business where outsourcing is prevalent, such as clinical development. Standards such as those developed by CDISC are already transforming how lab data are collected and managed. This in turn will make outsourcing more attractive while also fostering competition in the market. Data standards allow a more flexible and modular approach to solutions assembly and allow life science companies to be more opportunistic and agile in the operation of their businesses.

A standards-based approach creates a more cost-effective solution for customers than previous approaches. Service-oriented architectures offer real benefits to the organizations deploying them, and this is especially true for life science organizations. These architectures can create significant opportunities by reducing the cost and complexity of business operations in the following ways:

•            Application Integration — Web services simplify the integration of software applications. Most vendors have begun to package and deliver Web services for many common business data requirements.

•           Process Analytics — Enhanced data integration coupled with dynamic information assembly in a portal environment supports improved decision-making. Portals and advanced analytics work better together.

•            Platform Virtualization — Service-oriented architectures are inherently Internet friendly, supporting the centralization and virtualization of IT resources. Such architecture supports the consolidation of application instances and the associated IT infrastructure.

•            Compliance — Compliance investments will remain a top priority for life science companies. Substantial ongoing investments will be required to meet a long list of new requirements. Web services offer a better approach for companies trying to “future proof” their infrastructure to meet the needs of emerging compliance requirements.

•            Business Process Change — Web services make it easier and less costly to implement business process change. Outsourcing, compliance, acquisitions, and process improvement all drive change into the IT environment, and Web services make all of these changes easier.

When considered in aggregate, it seems the biggest potential advantage to come from Web services is increased innovation. By reducing the cost and complexity of change, Web services increase the ability to improve operations through innovation. By increasing the rate of change, we improve the odds of finding a better or optimal process or solution. Delivering improved rates of innovation and change to the organization may be the largest value a company gets from Web services.

Scott Lundstrom is VP Research, Health Industry Insights. E-mail: slundstrom@lifescience-insights.com.

 

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1



White Papers & Special Reports

sgi - whp 1
Turning Genomics Data into Practical Insight
Sponsored by SGI

With worldwide sequencing capacity approaching 13 quadrillion DNA bases annually turning genomics data into knowledge is a true computational challenge. Read this paper and learn how the SGI UV coherent shared memory platform can:  

  • Speed results time while cost competitively tackling the most difficult computational problems across all omics disciplines. 
  • Push performance by scaling to extraordinary levels, up to 256 sockets (2,560 cores, 4,096 threads) per single system (one OS image). 

Provide support for up to 16TB of coherent shared memory in a single system image enabling extreme efficiency across a wide range of compute demands. 



accerlys-logo_2012_wh
New Complimentary Market Survey…
Collaborations and Communications Within Drug Discovery Research
Sponsored by Accelrys
This survey was conducted by the Cambridge Healthtech Media Group in January, 2012. It was sponsored by Accelrys related to their HEOS initiative to gather valid information around externalizing collaborative research while improving communications in the cloud. With 310 qualified industry respondents the survey findings reveal useful usage and trends patterns.  An insightful follow-on discussion and webinar related to this survey, and the HEOS by Scynexis SaaS portal is also available on the Bio-IT World website for complementary viewing.
 


Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000
 

Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET. 

Apply at http://jobs.tessella.com   

 

oxford nanopore logo 


 Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes.  As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers.  This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions.  It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules.  It is therefore suitable for use in a variety of markets including scientific research and clinical applications.  As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team.  The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market.  This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company.  Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial  leadership, who wish to apply a fresh approach to existing markets.  Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries.  We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products.  Click to  Apply  


 

For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .